Seeking Alpha

Anacor Pharma (ANAC) -22.8% premarket despite what the company calls positive preliminary...

Anacor Pharma (ANAC) -22.8% premarket despite what the company calls positive preliminary late-stage results for a study of its nail fungus infection drug. In the first Phase 3 study, 6.5% of patients treated with tavaborole met the primary endpoint of "complete cure." Shares may be suffering from a comparison with rival Valeant's (VRX) competing product, efinaconazole.
Comments (1)
  • Clayman32
    , contributor
    Comments (8) | Send Message
     
    Well what we expected became reality, poor results despite being statistically significant. What is the commercial viability of tavaborole, no one will in- license it and does it make sense for Anacor to hire its own sales force to market that one product? Will medicare and third party payers support a product with significantly lower efficacy than the Valeant product? Lots of laughable spinning on the conference call today regarding patients over 70 and percent involvement, how many patients over 70 and with 60% involvement did they actually enroll? These are non-factors as far as physician usage behavior goes, they will use it on whatever severity/age they want. Anacor copied valeant's protocol since it was public knowledge and used most of the same investigators, so important similarities. Get over it DP Dow/ Valeant has kicked your hinney so far. Good luck, the Guru
    29 Jan 2013, 12:29 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs